These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 27712766

  • 1. Eosinophils and Mast Cells in Aspirin-Exacerbated Respiratory Disease.
    Steinke JW, Payne SC, Borish L.
    Immunol Allergy Clin North Am; 2016 Nov; 36(4):719-734. PubMed ID: 27712766
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Factors driving the aspirin exacerbated respiratory disease phenotype.
    Steinke JW, Borish L.
    Am J Rhinol Allergy; 2015 Nov; 29(1):35-40. PubMed ID: 25590316
    [Abstract] [Full Text] [Related]

  • 4. Genetic and Epigenetic Components of Aspirin-Exacerbated Respiratory Disease.
    Dahlin A, Weiss ST.
    Immunol Allergy Clin North Am; 2016 Nov; 36(4):765-789. PubMed ID: 27712769
    [Abstract] [Full Text] [Related]

  • 5. Pathogenesis of Aspirin-Induced Reactions in Aspirin-Exacerbated Respiratory Disease.
    Cahill KN, Laidlaw TM.
    Immunol Allergy Clin North Am; 2016 Nov; 36(4):681-691. PubMed ID: 27712763
    [Abstract] [Full Text] [Related]

  • 6. Epithelial folliculin enhances airway inflammation in aspirin-exacerbated respiratory disease.
    Trinh HKT, Pham DL, Choi Y, Kim HM, Kim SH, Park HS.
    Clin Exp Allergy; 2018 Nov; 48(11):1464-1473. PubMed ID: 30126026
    [Abstract] [Full Text] [Related]

  • 7. Eosinophil production of prostaglandin D2 in patients with aspirin-exacerbated respiratory disease.
    Feng X, Ramsden MK, Negri J, Baker MG, Payne SC, Borish L, Steinke JW.
    J Allergy Clin Immunol; 2016 Oct; 138(4):1089-1097.e3. PubMed ID: 27423494
    [Abstract] [Full Text] [Related]

  • 8. Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease.
    Steinke JW, Liu L, Huyett P, Negri J, Payne SC, Borish L.
    J Allergy Clin Immunol; 2013 Oct; 132(4):856-65.e1-3. PubMed ID: 23806637
    [Abstract] [Full Text] [Related]

  • 9. PGE suppresses excessive anti-IgE induced cysteinyl leucotrienes production in mast cells of patients with aspirin exacerbated respiratory disease.
    Wang XS, Wu AY, Leung PS, Lau HY.
    Allergy; 2007 Jun; 62(6):620-7. PubMed ID: 17508965
    [Abstract] [Full Text] [Related]

  • 10. Mechanisms of Benefit with Aspirin Therapy in Aspirin-Exacerbated Respiratory Disease.
    Hill J, Burnett T, Katial R.
    Immunol Allergy Clin North Am; 2016 Nov; 36(4):735-747. PubMed ID: 27712767
    [Abstract] [Full Text] [Related]

  • 11. Aspirin activation of eosinophils and mast cells: implications in the pathogenesis of aspirin-exacerbated respiratory disease.
    Steinke JW, Negri J, Liu L, Payne SC, Borish L.
    J Immunol; 2014 Jul 01; 193(1):41-7. PubMed ID: 24890720
    [Abstract] [Full Text] [Related]

  • 12. Aspirin exacerbated respiratory disease: Current topics and trends.
    Rodríguez-Jiménez JC, Moreno-Paz FJ, Terán LM, Guaní-Guerra E.
    Respir Med; 2018 Feb 01; 135():62-75. PubMed ID: 29414455
    [Abstract] [Full Text] [Related]

  • 13. Mechanisms of aspirin desensitization.
    Burnett T, Katial R, Alam R.
    Immunol Allergy Clin North Am; 2013 May 01; 33(2):223-36. PubMed ID: 23639710
    [Abstract] [Full Text] [Related]

  • 14. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease.
    Buchheit KM, Cahill KN, Katz HR, Murphy KC, Feng C, Lee-Sarwar K, Lai J, Bhattacharyya N, Israel E, Boyce JA, Laidlaw TM.
    J Allergy Clin Immunol; 2016 May 01; 137(5):1566-1576.e5. PubMed ID: 26691435
    [Abstract] [Full Text] [Related]

  • 15. Pathogenesis of aspirin-exacerbated respiratory disease and reactions.
    Laidlaw TM, Boyce JA.
    Immunol Allergy Clin North Am; 2013 May 01; 33(2):195-210. PubMed ID: 23639708
    [Abstract] [Full Text] [Related]

  • 16. Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.
    Liu T, Kanaoka Y, Barrett NA, Feng C, Garofalo D, Lai J, Buchheit K, Bhattacharya N, Laidlaw TM, Katz HR, Boyce JA.
    J Immunol; 2015 Oct 15; 195(8):3537-45. PubMed ID: 26342029
    [Abstract] [Full Text] [Related]

  • 17. Effect of TGF-β1 on eosinophils to induce cysteinyl leukotriene E4 production in aspirin-exacerbated respiratory disease.
    Choi Y, Sim S, Lee DH, Lee HR, Ban GY, Shin YS, Kim YK, Park HS.
    PLoS One; 2021 Oct 15; 16(8):e0256237. PubMed ID: 34437574
    [Abstract] [Full Text] [Related]

  • 18. Suppression of aspirin-mediated eosinophil activation by prostaglandin E2: Relevance to aspirin and nonsteroidal anti-inflammatory drug hypersensitivity.
    Pal K, Ramsden M, Shim YM, Borish L, Payne SC, Steinke JW.
    Ann Allergy Asthma Immunol; 2019 Nov 15; 123(5):503-506. PubMed ID: 31513909
    [Abstract] [Full Text] [Related]

  • 19. Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease.
    Mitsui C, Kajiwara K, Hayashi H, Ito J, Mita H, Ono E, Higashi N, Fukutomi Y, Sekiya K, Tsuburai T, Akiyama K, Yamamoto K, Taniguchi M.
    J Allergy Clin Immunol; 2016 Feb 15; 137(2):400-11. PubMed ID: 26194538
    [Abstract] [Full Text] [Related]

  • 20. Systemic expression of inflammatory mediators in patients with chronic rhinosinusitis and nasal polyps with and without Aspirin Exacerbated Respiratory Disease.
    Pezato R, Świerczyńska-Krępa M, Niżankowska-Mogilnicka E, Holtappels G, De Ruyck N, Sanak M, Derycke L, Van Crombruggen K, Bachert C, Pérez-Novo CA.
    Cytokine; 2016 Jan 15; 77():157-67. PubMed ID: 26615369
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.